Saturday 17 October 2026
Export VTGN’s income statement to Excel — free account
VistaGen Therapeutics, Inc.
VTGN Healthcare Biotechnology
VistaGen Therapeutics, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.3 million, up 161.1% from fiscal 2025. In the quarter to June 2026, revenue grew 504.9%, EPS grew 36.2% and free cash flow grew 22.2%, each against the same quarter a year earlier.
0.20
0.01
−4.76%
Follow VTGN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
176.02 | 35.28 | 17.10 | 3.95 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(9.22) | (1.58) | (1.34) | (0.67) | |
P/B ratio |
1.91 | 0.55 | 0.61 | 0.40 | |
Price to Tangible BV |
1.91 | 0.55 | 0.61 | 0.40 | |
EV/Sales |
80.51 | (32.39) | (12.13) | (5.41) | |
EV/EBITDA |
0.00 | 0.36 | 0.21 | 0.19 | |
EV/Operating CF |
(1.10) | 0.42 | 0.23 | 0.22 | |
EV/FCF |
(1.09) | 0.42 | 0.23 | 0.22 | |
Quick Ratio |
5.66 | 4.57 | 3.55 | 2.84 | |
Current Ratio |
5.79 | 4.67 | 3.67 | 3.07 | |
Net Debt/EBITDA |
3.83 | 3.15 | 2.70 | 2.36 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.01 | 0.02 | 0.05 | |
Operating CF/Net income |
0.71 | 0.93 | 1.00 | 1.13 | |
Capex/Depreciation |
0.65 | 0.30 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
6,168.60% | 4,694.06% | 2,835.78% | 738.89% | |
Selling, General and Administrative Expense of Revenue |
1,703.88% | 1,856.77% | 868.32% | 265.45% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
424.81% | 361.72% | 191.59% | 67.14% | |
Graham Net Nets |
0.51 | 1.76 | 1.56 | 2.33 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(53.52%) | (286.36%) | (321.05%) | (721.74%) | |
Free Cash Flow Yield |
(41.89%) | (217.18%) | (306.82%) | (631.72%) | |
Revenue per Share |
0.01 | 0.01 | 0.01 | 0.03 | |
Operating CF per Share |
(0.38) | (0.42) | (0.43) | (0.34) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.39) | (0.42) | (0.43) | (0.34) | |
Cash per Share |
2.16 | 1.46 | 1.19 | 0.74 | |
Shareholders Equity per Share |
1.86 | 1.21 | 0.93 | 0.57 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.86 | 1.21 | 0.93 | 0.57 | |
Free Cash Flow |
(13.82) | (17.66) | (16.20) | (14.71) | |
Working Capital |
65.29 | 49.72 | 34.15 | 23.12 | |
Capital Expenditures |
(0.06) | (0.03) | 0.00 | — | |
Net Current Asset Value |
64.34 | 49.11 | 33.90 | 23.06 | |
EV/EBIT |
0.00 | 0.37 | 0.21 | 0.19 | |
Capex to Sales |
0.23 | 0.09 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
1.27 | 1.16 | 1.09 | 0.74 | |
Average Assets |
91.71 | 78.68 | 66.45 | 52.33 | |
Average Common Equity |
79.66 | 66.02 | 52.96 | 40.62 |
Columns are period end dates